Moberg Pharma expects to announce phase II data for BUPI in January

STOCKHOLM, December 22, 2015. Moberg Pharma AB (OMX: MOB) today announced that
topline data from the clinical phase II-study for BUPI is expected to be
announced in January
The BUPI lozenge is investigated in a clinical phase II study with the aim of
demonstrating an added benefit to standard pain treatment. Earlier this year,
the inclusion period was extended after an amendment of the inclusion criteria
which introduced a threshold pain level for patients to be included in the
study.

“In total, 32 patients meeting the amended inclusion criteria have now completed
the study. We expect to announce topline data in January”, said Kjell Rensfeldt,
VP R&D of Moberg Pharma AB.

About Oral Mucositis and BUPI
Oral mucositis (“OM)” is a painful inflammation and ulceration of the mucous
membranes lining the mouth. OM is a common and often debilitating complication
of cancer treatment which affects 80% of patients with head and neck cancer
receiving radiotherapy, almost all patients undergoing bone marrow
transplantation, and a wide range of patients receiving chemotherapy. OM makes
the patient less likely to comply with their cancer treatment, increases
mortality and morbidity and contributes to rising health care costs. In the
U.S., every year approximately 400 000 patients suffer from OM during cancer
therapy.

The BUPI technology encompasses novel lozenge formulations of bupivacaine, a
local anesthetic with a well-established long acting effect, currently available
on the market for other indications as an injectable. A BUPI lozenge is
currently investigated in an ongoing clinical phase II study.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8:30 am (CET) on December 22, 2015.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Kjell Rensfeldt, VP R&D, Telephone: +46 (0)70 - 712 45 32, E-mail:
kjell.rensfeldt@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focuses on innovative drug
delivery of proven compounds and include two phase II assets, MOB-015
(onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company’s shares are listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further
information, please visit: www.mobergpharma.com.